Hospital Acquired Infections Therapeutics Market – By Drug Type, By Route of Administration, By Infection Type, & Global Forecast, 2024 – 2032

Hospital Acquired Infections Therapeutics Market Size

The global hospital acquired infections therapeutics market size was valued at USD 12.5 billion in 2023 and is expected to exhibit growth at a CAGR of 3.2% from 2024 – 2032. The progression of the industry is attributed to increasing prevalence of healthcare acquired infections, increasing emphasis on better patient care, and active government involvement in containing hospital acquired infections.
 

The prevalence of HAIs is rising due to factors such as increased hospital admissions, longer hospital stays, and the growing use of invasive devices. These infections, including urinary tract infections, pneumonia, and bloodstream infections, are driving the demand for effective therapeutic interventions. The increasing number of immunocompromised patients also contributes to the rise in HAIs.
 

The development of new and more effective antimicrobial therapies, including antibiotics and antifungals, is a key driver of the HAI therapeutics market. Pharmaceutical companies are investing heavily in research and development to combat antibiotic-resistant strains of bacteria. The availability of advanced therapeutics tailored to specific pathogens and infection types is improving patient outcomes and driving industry progression.
 

Hospital acquired infections therapeutics refers to a range of medical treatments designed to prevent, control, and treat infections acquired during hospital stays, often resistant to standard antimicrobial therapies.

Hospital Acquired Infections Therapeutics Market Trends

The first trend is the increasing use of rapid diagnostic tests and molecular diagnostics, which enable the swift identification of pathogens, allowing for more targeted and effective treatments. Another trend is the growing focus on antibiotic stewardship programs to manage and optimize the use of antibiotics, thereby reducing the incidence of antibiotic-resistant infections.
 

• There is a growing focus on developing novel antimicrobial agents, such as bacteriophages and monoclonal antibodies, to combat the rising threat of multi-drug-resistant organisms. Additionally, the integration of artificial intelligence and machine learning into infection control is gaining momentum, offering predictive analytics to anticipate outbreaks and optimize treatment protocols.
   
• Emphasis on infection prevention is also increasing, with advancements in sterilization techniques and the use of enhanced protective barriers in healthcare settings playing a critical role in reducing healthcare-associated infections (HAIs). Moreover, the expansion of telemedicine and remote monitoring technologies is improving HAI management by providing timely and efficient care, particularly in outpatient settings.
   

Hospital Acquired Infections Therapeutics Market Analysis

Based on drug type, the market is classified into antibacterial drugs, antiviral drugs, antifungal drugs, and other drug types. The antibacterial drugs segment generated the highest revenue of USD 9.2 billion in 2023.
 

• Antibacterial drugs are a cornerstone in the treatment of HAIs, holding a substantial market share. The increasing prevalence of antibiotic-resistant bacteria in healthcare settings has intensified the demand for potent antibacterial drugs. These medications are crucial for treating various bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile.
   
• The ongoing development of new antibiotics, particularly those targeting resistant strains, is essential to address the challenges posed by antibiotic resistance. Pharmaceutical companies are investing heavily in research to discover novel compounds and develop combination therapies to enhance the efficacy of existing drugs.
   

Based on route of administration, the hospital acquired infections therapeutics market is categorized into intravenous (IV), oral, topical, and inhalation. The intravenous (IV) segment generated the highest revenue of USD 5.7 billion in 2023.
 

• The intravenous (IV) route is the most commonly used method for administering medications in the treatment of HAIs. IV administration is preferred because it allows for rapid delivery of drugs directly into the bloodstream, ensuring quick onset of action, especially in severe infections where immediate intervention is critical.
   
• This route is particularly important in hospital settings where patients often present with serious, life-threatening infections that require high concentrations of antibiotics or other therapeutic agents. The precise control over dosage and the ability to administer continuous infusions make IV administration an ideal choice for managing complex and severe infections.
   

Based on infection type, the hospital acquired infections therapeutics market is categorized into surgical site infections, bloodstream infections, urinary tract infections, ventilator-associated pneumonia, and other hospital infections. The surgical site infections segment generated the highest revenue of USD 5.2 billion in 2023.
 

• Surgical Site Infections (SSIs) represent a significant portion of healthcare-associated infections (HAIs), positioning them as a key segment in the market. These infections occur at the incision site post-surgery and are influenced by factors such as patient health, surgery duration, and the operating room environment.
   
• The rising number of surgical procedures, especially in aging populations, increases the risk of SSIs. Consequently, there is a growing demand for targeted therapeutic interventions, including advanced wound care products and specialized antibiotics, to manage and prevent SSIs.
   

North America hospital acquired infections therapeutics market accounted for USD 4.7 billion market revenue in 2023 and is anticipated to grow at a CAGR of 2.5% between 2024 – 2032 period.
 

• In North America, the demand for healthcare-associated infection (HAI) therapeutics is driven by the high incidence of HAIs and a well-established healthcare infrastructure. The region's large number of hospitals and healthcare facilities elevates the risk of HAIs, making effective infection control measures crucial.
   
• Furthermore, the presence of major pharmaceutical companies and ongoing R&D efforts contribute to the availability of advanced therapeutics. In the U.S., the high volume of hospital admissions and invasive procedures, such as surgeries and catheterizations, increases the prevalence of HAIs. The country’s robust healthcare system facilitates the adoption of cutting-edge infection control practices and therapeutic interventions.
   

U.S. hospital acquired infections therapeutics market accounted for USD 4.3 billion market revenue in 2023 and is estimated to record notable expansion between 2024 – 2032 period.
 

• The U.S. is a significant market for HAI therapeutics due to its large and diverse patient population. The country's healthcare system is equipped with state-of-the-art facilities and technologies that aid in the diagnosis and treatment of HAIs.
   
• Furthermore, stringent regulatory frameworks and guidelines ensure the availability and use of effective therapeutics. The rising incidence of antibiotic-resistant infections, such as MRSA, drives the demand for novel antibacterial agents. The U.S. government and private sector's investment in healthcare research further supports the development of new treatments for HAIs. In November 2022, Johns Hopkins Medicine received USD 10 million with an aim to optimize its antibiotic treatment for infections caused by bacteria.
   

UK hospital acquired infections therapeutics industry is projected to grow remarkably in the coming years.
 

• In the UK, the demand for HAI therapeutics is influenced by the National Health Service (NHS) policies and initiatives aimed at reducing HAIs. The country has implemented strict infection control measures in healthcare facilities, which include regular monitoring and reporting of infection rates.
   
• The UK government also supports the development and use of advanced therapeutic agents to manage HAIs. Additionally, the increasing awareness among healthcare providers and patients about the risks associated with HAIs contributes to the industry development.
   

Japan holds a dominant position in the Asia Pacific market.
 

• Japan has a well-established healthcare system and a high standard of infection control practices, which drive the demand for HAI therapeutics. The country has a growing elderly population, which is more susceptible to infections, including HAIs.
   
• The Japanese government has implemented policies to promote the use of advanced therapeutics and improve infection control measures in healthcare facilities. Additionally, Japan's focus on innovation and technology in healthcare supports the development of new treatments for HAIs. The country's pharmaceutical industry is also actively involved in research and development activities, contributing to the availability of novel therapeutics.
   

Hospital Acquired Infections Therapeutics Market Share 

Several leading companies, such as Pfizer, Merck & Co., and GlaxoSmithKline, are actively involved in the development of new antimicrobial agents and therapies for HAIs. Recent industry developments include the approval of novel antibiotics and the expansion of research programs focused on multi-drug-resistant pathogens.
 

Hospital Acquired Infections Therapeutics Market Companies

Prominent players operating in the hospital acquired infections therapeutics industry include:

• Abbott
• AbbVie
• Allergan Plc
• Eugia Pharma
• Bayer
• DAIICHI SANKYO COMPANY
• F. Hoffmann-La Roche
• Glenmark Pharmaceuticals
• GSK
• Hikma Pharmaceuticals
• Melinta Therapeutics
• Merck & Co.
• Pfizer
• Sanofi
• Viatris
   

Hospital Acquired Infections Therapeutics Industry News:

• In October 2023, Spartan Medical Inc. launched a new campaign to raise awareness about surgical site infections (SSIs) and their consequences across the U.S. This strategy aims to educate healthcare professionals and patients about the risks associated with SSIs and the importance of prevention, thereby driving demand for advanced infection control measures and therapeutic solutions. The campaign strengthens Spartan Medical’s position in the infection control market, highlighting its commitment to addressing critical healthcare challenges.
   
• In April 2024, Basilea Pharmaceutica International Ltd. achieved a significant milestone by receiving FDA approval for its new drug, Zevtera, designed to treat bloodstream infections. This approval marks a key strategic move, positioning Basilea as a leader in the HAI therapeutics market. Zevtera’s approval will expand treatment options for severe infections, contributing to improved patient outcomes and reinforcing Basilea's market presence with innovative solutions.
   

The hospital acquired infections therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Antibacterial drugs
• Antiviral drugs
• Antifungal drugs
• Other drug types

Market, By Route of Administration

• Intravenous (IV)
• Oral
• Topical
• Inhalation

Market, By Infection Type

• Surgical site infections
• Bloodstream infections
• Urinary tract infections
• Ventilator-associated pneumonia
• Other hospital infections

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE